Radretumab

Radretumab is a radioimmunotherapy agent that is used in the treatment of malignant pleural mesothelioma. It is a monoclonal antibody that is linked to a radioisotope, which allows it to deliver a dose of radiation directly to the cancer cells.

Mechanism of action[edit | edit source]

Radretumab works by binding to a specific protein found on the surface of mesothelioma cells. Once it is attached, the radioisotope releases radiation that kills the cancer cells. This targeted approach helps to minimize damage to healthy cells.

Clinical trials[edit | edit source]

Radretumab has been tested in several clinical trials. In a phase II trial, it was found to improve survival in patients with malignant pleural mesothelioma who had previously been treated with chemotherapy. Further trials are ongoing to confirm these results and to test the drug in combination with other treatments.

Side effects[edit | edit source]

Like all cancer treatments, radretumab can cause side effects. These can include nausea, vomiting, and fatigue. More serious side effects can include bone marrow suppression, which can lead to a decrease in the number of blood cells and an increased risk of infection.

See also[edit | edit source]

Radretumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.